Clinical trials: Peptide Receptor Radionuclide Therapy (PRRT)
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or…
- Trial name
- NCT03457948
- Testing
- Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nicholas Fidelman, MD
Gastro-entero-pancreatic Neuroendocrine Tumors
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
This is a randomized phase II, parallel group study. Patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) well differentiated G1 - G2 (ki67≤ 20%) and G3 (ki67≤ 50%), somatostatin receptor (SSR) positive and…
- Trial name
- Lu-Ca-S (NCT02736448)
- Testing
- Capecitabine, Lu-PRRT, SS-LAR
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neuroendocrine Tumors
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
Well-differentiated neuroendocrine tumors (WDNETs) are uncommon neoplasms with an increasing number of new cases reported in the annual statistics of the Instituto Nacional de Cancerología (INC).
- Trial name
- NCT02125474
- Testing
- [177Lu] DOTA-TATE
- Where
- Colombia
- Volunteers
- 39 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Neuroendocrine Tumor, Liver Metastases
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options.
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- LUTARTERIAL (NCT04837885)
- Testing
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection
- Where
- 4 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Neuroendocrine Tumors
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to…
- Trial name
- NCT04194125
- Testing
- 177Lu-DOTATOC
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- University of Warmia and Mazury
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with…
- Trial name
- REMAIN (NCT07842172)
- Testing
- Somatostatin Analogue(s)
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Washington University School of Medicine